Global X Artificial Intelligence & Technology ETF vs Recursion Pharmaceuticals Inc — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $63.5, while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: Global X Artificial Intelligence & Technology ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AIQ | RXRX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $6.79 |
52-Week Low | $43.88 | $2.84 |
Market Cap | — | $1.81B |
Enterprise Value | — | $1.33B |
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.69, up 0.28% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. The stock recently crossed above its 200-day moving average of $56.52, indicating positive momentum. Recent news highlights AIQ's outperformance versus the Nasdaq and its role in the AI investment theme, though financial ratios are not provided in the snapshot.
The outlook for AIQ is tied to the AI sector's growth, with potential from thematic exposure and rebalancing strategies. Risks include high fees, sector volatility, and dependence on AI adoption trends. Analyst sentiment is mixed, with some praising diversification benefits while others note valuation concerns amid rapid gains.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Trailing returns across standard periods
Latest headlines on both assets
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →